Search Videos and More

Showing 61 - 72 of 578 results

Previous| 1... 5 | 6 | 7 ...49 |Next


Head and Neck, Breast, Lung and Survivorship Studies Headline Dana-Farber Research at AACR Annual Meeting 2025 News

Head and Neck, Breast, Lung and Survivorship Studies Headline Dana-Farber Research at AACR Annual Meeting 2025

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.
Effects of Immunotherapy Can Last After Treatment Stops According to Dana-Farber Study News

Effects of Immunotherapy Can Last After Treatment Stops According to Dana-Farber Study

Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non-small cell lung cancer
Dana-Farber Research News 04.15.2025 News

Dana-Farber Research News 04.15.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 16 through March 31.
Dana-Farber Researchers Receive AACR 2025 Scientific Achievement Awards News

Dana-Farber Researchers Receive AACR 2025 Scientific Achievement Awards

Matthew Meyerson, MD, PhD, FAACR, Toni K. Choueiri, MD, and Alice T. Shaw, MD, PhD, have been selected by the American Association for Cancer Research (AACR) as recipients of 2025 Scientific Achievement Awards.
Years of Research Help Forge a New Path in Hodgkin Lymphoma Treatment News

Years of Research Help Forge a New Path in Hodgkin Lymphoma Treatment

Medical advances tend to unfold slowly over many years, fueled by successive clinical studies that build upon each other and together provide the evidence needed to change patient care.
Novel Genomic Screening Tool Enables Precision Reverse-Engineering of Genetic Programming in Cells News

Novel Genomic Screening Tool Enables Precision Reverse-Engineering of Genetic Programming in Cells

Collaborative research led by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center defines a novel approach to understanding how certain proteins called transcription factors determine which genetic programs will drive cell growth and maturation.
Dana-Farber Research News 04.01.2025 News

Dana-Farber Research News 04.01.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 1 through March 15.
FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research News

FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research

FDA decision establishes cabozantinib as a standard of care treatment for patients with previously treated advanced neuroendocrine tumors
Potential Targeted Therapy for Pediatric Brain Cancer Identified by Dana-Farber/Boston Children's Team News

Potential Targeted Therapy for Pediatric Brain Cancer Identified by Dana-Farber/Boston Children's Team

An international team of clinical collaborators, led by physician scientists from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, performed a first-ever clinical test of the targeted therapy avapritinib in pediatric and young patients with a form of high-grade glioma.
AI Learns Genomic “Language” to Advance Cancer Treatment News

AI Learns Genomic “Language” to Advance Cancer Treatment

The human genome is a sequence of Ts, Gs, Cs, and As that is about 3 billion letters long.  And, says Bradley Bernstein, MD, PhD, chair of Dana-Farber’s Department of Cancer Biology, “there’s no dictionary or guide for reading it.”  
Treatment of Recurrent Endometrial Cancer with Metformin, Letrozole, and Abemaciclib is Safe and Promising, Dana-Farber Research Shows News

Treatment of Recurrent Endometrial Cancer with Metformin, Letrozole, and Abemaciclib is Safe and Promising, Dana-Farber Research Shows

A combination, triplet therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in nearly all patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer, results from a recent phase 2 clinical trial show.
Dana-Farber Research News 03.15.2025 News

Dana-Farber Research News 03.15.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from February 16 through February 28.

Showing 61 - 72 of 578 results

Previous| 1... 5 | 6 | 7 ...49 |Next